Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Sep;47(9):1041-1045.
doi: 10.1111/1346-8138.15371. Epub 2020 Jul 1.

Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment

Wei-Hsi Lin  1 , Kang-Yun Lee  2 , Woan-Ruoh Lee  1   3   4 , Yi-Hsien Shih  1   3   4
Affiliations
Case Reports

Durvalumab-induced de novo annular psoriasiform drug eruption successfully treated with a combination of narrowband ultraviolet B phototherapy and topical treatment

Wei-Hsi Lin et al. J Dermatol. 2020 Sep.

Abstract

Immune checkpoint inhibitors, including anti-programmed death 1 and anti-programmed death ligand 1, have become prominent treatment options for various types of cancers. However, immune checkpoint inhibitors are associated with various cutaneous adverse events, one of which is psoriasiform drug eruption. Some cases of psoriasiform drug eruption can only be controlled through the cessation of immune checkpoint inhibitors and administration of systemic immunosuppressants, such as corticosteroids and methotrexate. However, no clear guideline is available on the management of this specific rash, and the use of systemic immunosuppressants is contraindicated in selected conditions. In this article, we report a case of annular psoriasiform drug eruption induced by an anti-programmed death ligand 1 monoclonal antibody, durvalumab. The patient responded well to the combination of phototherapy and topical treatment, which allowed continuation of durvalumab treatment without concomitant systemic immunosuppressants in a 2-year follow up.

Keywords: anti-programmed death ligand 1; durvalumab; immune checkpoint inhibitor; phototherapy; psoriasis.

PubMed Disclaimer

References

    1. Min Lee CK, Li S, Tran DC et al. Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: a retrospective case-control study. J Am Acad Dermatol 2018; 79(6): 1047-1052.
    1. Belum VR, Benhuri B, Postow MA et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 2016; 60: 12-25.
    1. Sanlorenzo M, Vujic I, Daud A et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol 2015; 151(11): 1206-1212.
    1. Antonia SJ, Villegas A, Daniel D et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 2017; 377(20): 1919-1929.
    1. Voudouri D, Nikolaou V, Laschos K et al. Anti-PD1/PDL1 induced psoriasis. Curr Probl Cancer 2017; 41(6): 407-412.

Publication types